MGC018

DRUG2 trials

Sponsors

Macrogenics Inc., Georgetown University

Conditions

Extensive-stage Small-cell Lung CancerMetastatic Castration-resistant Prostate Cancer

Phase 2

A Phase 2, Randomized, Open-Label Study of Two Dose Levels of Vobramitamab Duocarmazine in Participants with Metastatic Castration-Resistant Prostate Cancer (TAMARACK)

CompletedCTIS2022-501078-20-00

Macrogenics Inc.Metastatic Castration-resistant Prostate Cancer

Start: 2023-05-15End: 2025-01-23Target: 61Updated: 2025-02-04

MGC018 in Patients With Relapsed or Refractory Extensive-Stage Small-Cell Lung Cancer

Active, not recruitingNCT06227546

Georgetown UniversityExtensive-stage Small-cell Lung Cancer

Start: 2024-04-15End: 2026-05-31Updated: 2025-07-08